Dengue Vaccines development and progress towards vaccine has increased over the past few years

 

  Dengue fever is a tropical disease spread by mosquitos that are caused by the dengue virus. 3 to 14 days after infection, symptoms appear. A high fever, headache, vomiting, muscle, and joint pains, and a distinct skin rash are all potential symptoms. In most cases, recovery takes two to seven days. In a small percentage of cases, the disease progresses to dengue hemorrhagic fever, which causes bleeding, low levels of blood platelets, and blood plasma leakage, or to dengue shock syndrome, which causes dangerously low blood pressure.

  Dengue is spread by several Aides genus female mosquitoes, most notably Aides. The virus has five serotypes; infection with one type usually results in lifelong immunity to that type but only temporary immunity to the others. Subsequent infection with a different type raises the possibility of severe complications. . Dengue vaccines are a vaccine used to protect humans from dengue fever to confirm the diagnosis, a number of tests are available, including the detection of antibodies to the virus or its RNA.

  Dengue virus has grown dramatically in the last 20 years, becoming one of the most dangerous mosquito-borne human pathogens that tropical countries must contend with. According to current estimates, up to 390 million dengue infections occur each year, with many of these infections being asymptomatic or subclinical.

  The dengue virus causes dengue fever (DENV). It is a mosquito-borne, single positive-stranded RNA virus in the Flaviviridae family, genus Flavivirus. Four serotypes of the virus have been identified, with a fifth rumored but yet to be confirmed, all of which can cause the full range of disease. Even though, scientists' understanding of the dengue virus may be misconstrued, as a dynamic process instead of distinct antigenic groups appears to exist. The same study discovered 47 different strains of the dengue virus.

  Dengue virus was transmitted in sylvatic cycles between mosquitos of the genus Aides and nonhuman primates in Africa, Southeast Asia, and South Asia until a few hundred years ago, with rare emergences into human populations. Dengue virus's global spread, on the other hand, has coincided with its emergence from sylvatic cycles, and the primary lifecycle now only involves transmission between humans and Aides mosquitos. Dengue vaccines are a vaccine used to protect humans from dengue fever.  One version, known as CYD-TDV and sold under the brand name is commercially available as of 2021. The vaccine is only recommended for people who have previously been infected with dengue fever or for populations where the majority of people have previously been infected.